Device_News
15 October 2018

Draft BASHH gonorrhoea guidelines recommend ciprofloxacin susceptibility testing

Products

Updated Draft BASHH guidelines on the management of gonorrhoea indicate ciprofloxacin as preferential treatment over ceftriaxone if susceptibility is known.

ResistancePlus® GC will be the first commercially available molecular test to inform ciprofloxacin susceptibility status. Current gonorrhoea surveillance data indicate up to 80% of infections in some regions are susceptible to ciprofloxacin treatment.

Read full guidelines currently open for consultation.

Print page